[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"churg-strauss-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:churg-strauss-syndrome":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100283245","vcrc-tissue-repository-100283245",false,"NCT02967068","VCRC Tissue Repository","VCRC Tissue Biorepository Collection Protocol","Inclusion Criteria:\n\n* A participant will be deemed eligible for this study if the participant is\u002Fwas enrolled in another one of the VCRC observational\u002Flongitudinal protocols (5502, 5503, 5504, 5505, 5506, 5507, 5563) and\u002For one of the VCRC interventional studies (5522, 5523, 5526, 5527, or 5562).\n\nExclusion Criteria:\n\n* Inability to give informed consent (or their guardians in the case of children) and to sign the consent form.\n* Unwilling to allow the use of their tissue for research.","ALL",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.",[23,24,25,26,27,28,29,30,31,32,33],"Aortitis","Cutaneous Vasculitis","Eosinophilic Granulomatosis With Polyangiitis","Giant Cell Arteritis","Granulomatosis With Polyangiitis (Wegener's)","Henoch-Schonlein Purpura","IgA Vasculitis","Microscopic Polyangiitis","Polyarteritis Nodosa","Takayasu Arteritis","Churg-Strauss Syndrome",[35,36,37,38,39,40,41,42],"CSS","EGPA","GCA","GPA","MPA","PAN","TAK","HSP","RECRUITING","2026-01-21",{"date":46,"type":47},"2026-01-22","ACTUAL",{"date":49,"type":47},"2016-11",{"date":51,"type":19},"2028-12",{"name":53,"class":54},"University of Pennsylvania","OTHER",8,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":73,"locationsCount":74},"100081347","longitudinal-study-for-eosinophilic-granulomatosis-with-polyangiitis-100081347","NCT00315380","Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis","Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis","Inclusion Criteria:\n\nPatients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.\n\nParent or guardian willing to provide informed consent, if applicable\n\nExclusion Criteria:\n\n\\- Inability to give informed consent and to sign the consent form",{"count":64,"type":19},700,"Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.",[25,33],[36,35],{"date":69,"type":47},"2026-01-23",{"date":71,"type":4},"2006-04",{"date":51,"type":19},{"name":53,"class":54},13]